 Connection
Thomas Campbell to Drug Resistance, Viral
This is a "connection" page, showing publications Thomas Campbell has written about Drug Resistance, Viral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.697 |
|
|
|
-
Campbell TB. Choice of an initial antiretroviral regimen in the resource-limited setting: the cost of virologic failure. Clin Infect Dis. 2008 Sep 01; 47(5):723-5.
Score: 0.261
-
Campbell TB, Katzenstein D. Antiretroviral rounds. Resistance: how do you know if you don't know? AIDS Clin Care. 2005 Mar; 17(3):26-7.
Score: 0.205
-
Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, Supparatpinyo K, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15; 60(10):1541-9.
Score: 0.102
-
Campbell TB, Rapaport E, Schooley RT, Kuritzkes DR. Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis. 2004 Jul 15; 190(2):257-66.
Score: 0.049
-
Thio CL, Smeaton L, Hollabaugh K, Saulynas M, Hwang H, Saravanan S, Kulkarni S, Hakim J, Nyirenda M, Iqbal HS, Lalloo UG, Campbell TB, Lockman S, Currier JS. Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS. 2015 Jun 19; 29(10):1173-82.
Score: 0.026
-
Zheng Y, Hughes MD, Lockman S, Benson CA, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96.
Score: 0.024
-
Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods. 2007 Dec; 146(1-2):136-46.
Score: 0.015
-
Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006; 11(5):619-23.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|